Ala Altaie: We Found That Mononuclear Cells From RA Patients Can Trigger Clot Formation
Ala Altaie, Research Fellow in Mesenchymal Stem Cell Biology at the Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, shared a post on LinkedIn:
”New paper out!
Why do some patients on JAK inhibitors develop venous thromboembolism (VTE) or pulmonary embolism (PE) without deep vein thrombosis?
In our latest study led by Paula David and colleagues, we found that mononuclear cells from RA patients can trigger clot formation—especially when exposed to JAK inhibitors like tofacitinib.
This process, known as immunothrombosis, links the immune system to coagulation through increased Factor III production.
Panel A: Clots formed faster with tofacitinib
Panel B: Clot strength was higher
These findings shed light on the immune–coagulation connection behind JAK inhibitor–associated clots.
Read more.”
Title: Augmentation of immunothrombosis as a key mechanism underlying JAK inhibition associated hypercoagulability in rheumatoid arthritis
Authors: Paula David, Tom Macleod, Ala Altaie, Yu Shi, Kerem Abacar, Sami Giryes, Gabrielle de Mello Santos, Payal Ganguly, Mark Harland, Chi Wong, Andrew Scarsbrook, Paul Emery, Kulveer Mankia, Shouvik Dass, Andrea Di Matteo, Benazir Saleem, Cédric Duval, Robert Ariëns, Dennis McGonagle
Stay updated with Hemostasis Today.
-
Oct 10, 2025, 16:15Roshan PK: Breaking Down Pulmonary Embolism Treatment By Risk Level
-
Oct 10, 2025, 12:21Chris Barber Echoes PPTA’s Call to Recognize the Lifesaving Work of Plasma Collection Teams Worldwide
-
Oct 10, 2025, 12:14William Aird: Thalassemia Trait is a Quiet Experiment of Nature
-
Oct 9, 2025, 19:53Wilfried Dinh: Top 10 Thrombosis And Antithrombotic Therapy Papers Of 2024
-
Oct 9, 2025, 13:12Abdul Mannan - Ferritin After IV Iron: Timing Matters
-
Oct 10, 2025, 12:23Bhavya Venkatesh: Talin Autoinhibition Is Required For Normal Hemostasis
-
Oct 10, 2025, 12:19Divyaswathi Citla Sridhar: Excited to Share Our Multicenter Study on Platelet Function Disorders, Now Published
-
Oct 10, 2025, 12:18Roberta Gualtierotti: We Evaluated Different Variables of the Cleaved HK Method in C1-Inhibitor Defects
-
Oct 10, 2025, 12:17Jamie Madrigal And The Team - Mathematical Analysis Of Emicizumab: Affinity-Driven Complex Formation And Lipid-Surface Reactions
-
Oct 10, 2025, 03:09Giuseppe Lippi: We Show Here That Red Light Therapy Offers Promise in High-Risk Patients
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 7, 2025, 13:06Bobur Kholikov on iFlash Thrombosis Panel – D-Dimer
-
Oct 7, 2025, 03:502025 Nobel Prize: A Milestone for Autoimmunity Research - Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
-
Oct 10, 2025, 03:10Marilena Vrana: Plasma-Derived Medicines Are a Clear Example of Why A One-Size-Fits-All Approach Won’t Work
-
Oct 10, 2025, 03:07Nancy Di Salvo: It's IPAW 2025, How Could I Not Take a Moment to Thank Every Single Plasma Donor Out There?
-
Oct 10, 2025, 03:06Anita Brikman: Increasing Awareness of The Ongoing Need for Plasma Donors Is Vital to Ensuring Patient Access and Continuity of Care
-
Oct 10, 2025, 03:04Stephen Cornelissen: A New Plasma Drop Has Been Added to Lifeblood’s Blood Supply Tracker
-
Oct 10, 2025, 02:12Bethany Samuelson Bannow Welcomed to Department of Hematology and Medical Oncology at the Cancer Institute Cleveland Clinic